Microbe | MASI

Microbe Alteration of Therapeutic Substances

✅ Therapeutic substance that metabolized by Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Metabolism Type	Metabolites	Effects on Substance	Experimental System	Experimental Organism	Experimental Disease Condition	Alteration Mechanism	Alteration Outcome	Reference (PubMed ID)

Therapeutic Substance Alteration of Microbes

✅ Therapeutic Substances that affect the Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Substance Details	Effect on Microbe	Effect Strength	Experimental System	Experimental Organism	Experimental Disease Condition	Reference (PubMed ID)

Microbe Alteration of Herbal Substances

✅ Traditional medicines/herbs/herbal compounds that metabolized by Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Metabolism Type	Metabolites	Effects on Substance	Experimental System	Experimental Organism	Experimental Disease Condition	Alteration Mechanism	Alteration Outcome	Reference (PubMed ID)

Herbal Substances Alteration of Microbes

✅ Traditional medicines/herbs/herbal compounds that affect the Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Substance Details	Effect on Microbe	Effect Strength	Experimental System	Experimental Organism	Experimental Disease Condition	Reference (PubMed ID)

Dietary Substance Alteration of Microbe

✅ Dietary Substances alter the abundance of Bifidobacterium breve K-110

No data available!

Substance Name	Substance Category	Substance Subcategory	Substance Details	Effect on Microbe	Effect Strength	Experimental System	Experimental Organism	Experimental Disease Condition	Reference (PubMed ID)

Microbe Alteration of Environmental Substances

✅ Environmental Substances that metabolized by Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Metabolism Type	Metabolites	Effects on Substance	Experimental System	Experimental Organism	Experimental Disease Condition	Alteration Mechanism	Alteration Outcome	Reference (PubMed ID)

Environmental Substances Alteration of Microbes

✅ Environmental Substances that affect the Bifidobacterium breve K-110

Substance Name	Substance Category	Substance Subcategory	Substance Details	Effect on Microbe	Effect Strength	Experimental System	Experimental Organism	Experimental Disease Condition	Reference (PubMed ID)

Diseases Associated with the Alteration of Microbiota Composition

✅ Diseases associated with the microbe Bifidobacterium breve K-110

Microbiota Site	Disease Name	Disease Association Class	Disease Associated Abundence Change	Reference (PubMed ID)

Landscape of Bacteria-Substance-Disease Interaction/Association Network

⚠ About the network

The substances in "Bacteria-Substance-Disease Interaction/Association network" only cover therapeutic drugs. The network is presented for an intuitive visualization of the drugs that interact with microbiota bacteria, diseases that associated with microbiota bacteria changes, and disease-drug interactions. The interactive network is generated using Cytoscape.js.

How is the network built?

1. The first round of network build.
Bacteria-Drug edges: the bacteria-drug interactions recorded in MASI (irrespective of interaction direction).
Bacteria-Disease edges: the bacteria-disease associations recorded in MASI.
Disease-Drug edges: were extracted from Therapeutic Target Database (TTD) which provides approved disease indications of therapeutic drugs. So, disease-substance links presented here mean that drugs linked to a disease are used to treat this disease according to TTD database.

2. The second round of network build (network expansion).
Expend drug edges: drugs that associated with diseases included in the 1st round are added.
Expend disease edges: diseases that associated with drugs included in the 1st round are added.

Node shapes: drugs are presented with circles, diseases are presented with rectangles.
Node colors: drugs that interacted with the bacteria are colored with burgundy, diseases that associated with the microbiota bacteria changes are colored with dark green. Drugs and diseases that do not interact/associate with bacteria are in gray color.

Relative abundance landscape of Bifidobacterium breve K-110 in human gut microbiota samples

Abundance lanscape in healthy samples (by patients' age)

Abundance lanscape in healthy samples (by patients' country)

Abundance lanscape in disease samples

⚠ About the relative abundance profile

The relative taxonomical abundance data (pre-processed using a unified analysis pipeline) was retrieved from curatedMetagenomicData resource [Edoardo Pasolli, et al. Nat Methods. 2017;14(11):1023-1024]. Data retrieved here was pre-processed as unified relative abundance: at each taxonomic level (e.g., species, genus, family), the sum of microbial abundance of individual microbiota sample was 1, and relative abundance of each microbe was log10 transformed [relative abundance ranges from -7 to 0].

Healthy samples and disease samples (only disease types with >= 20 samples were included) were grouped by age periods, patients’ country, or disease type to plot the relative abundance landscape using ggplot2 R package.

Bifidobacterium breve K-110

Microbe Identification

Interactions between microbe and active substances